Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Diagnosis of prostate cancer using differentially expressed genes in stroma.

Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, Xia XQ, Xu Q, Pio R, Turan T, Koziol JA, Goodison S, Carpenter P, Wang-Rodriguez J, Simoneau A, Meyskens F, Sutton M, Lernhardt W, Beach T, Monforte J, McClelland M, Mercola D.

Cancer Res. 2011 Apr 1;71(7):2476-87. doi: 10.1158/0008-5472.CAN-10-2585.

2.

Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China.

Zhu J, Pan C, Jiang J, Deng M, Gao H, Men B, McClelland M, Mercola D, Zhong WD, Jia Z.

Oncotarget. 2015 Jun 30;6(18):16757-65.

3.

Expression changes in the stroma of prostate cancer predict subsequent relapse.

Jia Z, Rahmatpanah FB, Chen X, Lernhardt W, Wang Y, Xia XQ, Sawyers A, Sutton M, McClelland M, Mercola D.

PLoS One. 2012;7(8):e41371. doi: 10.1371/journal.pone.0041371. Epub 2012 Aug 1. Erratum in: PLoS One. 2012;7(9). doi: 10.1371/annotation/7de63575-e5c9-4f1d-bb45-fc6420e92c71.

4.

Gene expressional changes in prostate fibroblasts from cancerous tissue.

Reinertsen T, Halgunset J, Viset T, Flatberg A, Haugsmoen LL, Skogseth H.

APMIS. 2012 Jul;120(7):558-71. doi: 10.1111/j.1600-0463.2011.02865.x. Epub 2012 Jan 25.

PMID:
22716211
5.

Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.

Gregg JL, Brown KE, Mintz EM, Piontkivska H, Fraizer GC.

BMC Cancer. 2010 Apr 28;10:165. doi: 10.1186/1471-2407-10-165.

6.

Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer.

Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, Marker PC.

Cancer Res. 2005 Nov 15;65(22):10423-30.

7.

Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer.

Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle JC, Stamenkovic I.

PLoS One. 2011;6(5):e18640. doi: 10.1371/journal.pone.0018640. Epub 2011 May 18.

8.

Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.

Wikström P, Marusic J, Stattin P, Bergh A.

Prostate. 2009 Jun 1;69(8):799-809. doi: 10.1002/pros.20927.

PMID:
19189305
9.

The stromal genome heterogeneity between breast and prostate tumors revealed by a comparative transcriptomic analysis.

He K, Lv W, Zheng D, Cheng F, Zhou T, Ye S, Ban Q, Ying Q, Huang B, Chen L, Wu G, Liu D.

Oncotarget. 2015 Apr 20;6(11):8687-97.

10.

Global expression analysis of prostate cancer-associated stroma and epithelia.

Richardson AM, Woodson K, Wang Y, Rodriguez-Canales J, Erickson HS, Tangrea MA, Novakovic K, Gonzalez S, Velasco A, Kawasaki ES, Emmert-Buck MR, Chuaqui RF, Player A.

Diagn Mol Pathol. 2007 Dec;16(4):189-97.

PMID:
18043281
11.

Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.

Chakrabarti R, Robles LD, Gibson J, Muroski M.

Cancer Genet Cytogenet. 2002 Dec;139(2):115-25.

PMID:
12550771
12.

Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine.

Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, Pardee AB, Reddy GP.

Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2343-8. Epub 2007 Feb 5.

13.

Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.

Zhang X, Wang W, True LD, Vessella RL, Takayama TK.

Prostate. 2009 May 15;69(7):727-36. doi: 10.1002/pros.20920.

14.

Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts.

Zhao H, Peehl DM.

Prostate. 2009 Jun 15;69(9):991-1000. doi: 10.1002/pros.20946.

15.

Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.

Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA, Quale C.

BMC Genomics. 2013 Oct 8;14:690. doi: 10.1186/1471-2164-14-690.

16.

[Gene expression profiling in prostatic cancer].

Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Ikinger U, Kretzler M, Hollstein M, Gröne HJ.

Verh Dtsch Ges Pathol. 2002;86:165-75. Review. German.

PMID:
12647366
17.

Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes.

Ashida S, Orloff MS, Bebek G, Zhang L, Zheng P, Peehl DM, Eng C.

Clin Cancer Res. 2012 Mar 15;18(6):1578-87. doi: 10.1158/1078-0432.CCR-11-2535. Epub 2012 Jan 24.

18.

Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers.

Mengual L, Ars E, Lozano JJ, Burset M, Izquierdo L, Ingelmo-Torres M, Gaya JM, Algaba F, Villavicencio H, Ribal MJ, Alcaraz A.

Actas Urol Esp. 2014 Apr;38(3):143-9. doi: 10.1016/j.acuro.2013.07.012. Epub 2013 Oct 25. English, Spanish.

PMID:
24206626
19.

Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.

Zhao H, Ramos CF, Brooks JD, Peehl DM.

J Cell Physiol. 2007 Jan;210(1):111-21.

20.

Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium.

Schlicht M, Matysiak B, Brodzeller T, Wen X, Liu H, Zhou G, Dhir R, Hessner MJ, Tonellato P, Suckow M, Pollard M, Datta MW.

BMC Genomics. 2004 Aug 20;5(1):58.

Supplemental Content

Support Center